España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
AtriCure
ATRC
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$30.72
0.67
2.23%
At close: -
$30.72
0.00050
0.00%
After Hours: Dec 20, 4:01 PM EDT
Get Report
Comment
AtriCure (ATRC) Forecast
News
Earnings
AtriCure (ATRC) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for AtriCure (NASDAQ:ATRC) Stock
AtriCure Stock (NASDAQ: ATRC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, December 17, 2024
JP Morgan Assumes AtriCure at Overweight, Ann...
Benzinga Newsdesk
Monday, December 09, 2024
Cracking The Code: Understanding Analyst Reviews For AtriCure
Benzinga Insights
Canaccord Genuity Maintains Buy on AtriCure, ...
Benzinga Newsdesk
Wednesday, October 30, 2024
Canaccord Genuity Maintains Buy on AtriCure, ...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on AtriCure,...
Benzinga Newsdesk
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
JP Morgan Maintains Overweight on AtriCure, R...
Benzinga Newsdesk
UBS Maintains Buy on AtriCure, Raises Price T...
Benzinga Newsdesk
Atricure shares are trading higher after the ...
Benzinga Newsdesk
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Needham Maintains Buy on AtriCure, Raises Pri...
Benzinga Newsdesk
Tuesday, October 29, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Atricure shares are trading higher after the ...
Benzinga Newsdesk
ArtiCure Sees FY24 Revenue ~$459M-$462M Vs $4...
Benzinga Newsdesk
AtriCure Q3 2024 Adj. EPS $(0.17) Beats $(0.1...
Benzinga Newsdesk
Tuesday, October 15, 2024
AtriCure Announces Launch Of cryoSPHERE MAX P...
Benzinga Newsdesk
Tuesday, August 27, 2024
AtriCure Reports First Patient Has Been Treat...
Benzinga Newsdesk
Friday, August 23, 2024
AtriCure's AtriClip Receives Expanded CE-Mark Indication
Zacks
Thursday, August 22, 2024
AtriCure Receives Expanded Indication For Atr...
Benzinga Newsdesk
Wednesday, July 31, 2024
Navigating 6 Analyst Ratings For AtriCure
Benzinga Insights
BTIG Maintains Buy on AtriCure, Lowers Price ...
Benzinga Newsdesk
JP Morgan Maintains Overweight on AtriCure, L...
Benzinga Newsdesk
Stifel Maintains Buy on AtriCure, Lowers Pric...
Benzinga Newsdesk
Needham Maintains Buy on AtriCure, Lowers Pri...
Benzinga Newsdesk
Piper Sandler Maintains Overweight on AtriCur...
Benzinga Newsdesk
Tuesday, July 30, 2024
AtriCure Q2 2024 GAAP EPS $(0.17), Inline, Sa...
Benzinga Newsdesk
Tuesday, July 23, 2024
AtriCure Receives National Medical Products A...
Benzinga Newsdesk
Monday, July 08, 2024
Analyst Ratings For AtriCure
Benzinga Insights
Needham Reiterates Buy on AtriCure, Maintains...
Benzinga Newsdesk
Tuesday, June 18, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Watching AtriCure; Traders Circulating Unconf...
Benzinga Newsdesk
Thursday, May 02, 2024
Canaccord Genuity Maintains Buy on AtriCure, ...
Benzinga Newsdesk
AtriCure shares are trading lower after the c...
Benzinga Newsdesk
JP Morgan Maintains Overweight on AtriCure, L...
Benzinga Newsdesk
Cracking The Code: Understanding Analyst Reviews For AtriCure
Benzinga Insights
Needham Maintains Buy on AtriCure, Lowers Pri...
Benzinga Newsdesk
Wednesday, May 01, 2024
ArtiCure Sees FY24 Adj. EPS $(0.82)-$(0.74) V...
Benzinga Newsdesk
AtriCure Q1 2024 Adj EPS $(0.25) Misses $(0.2...
Benzinga Newsdesk
Tuesday, April 23, 2024
Oppenheimer Upgrades AtriCure to Outperform, ...
Benzinga Newsdesk
Thursday, April 18, 2024
AtriCure Launched cryoSPHERE+ Cryoablation Pr...
Benzinga Newsdesk
Wednesday, April 10, 2024
Key Takeaways From AtriCure Analyst Ratings
Benzinga Insights
Needham Reiterates Buy on AtriCure, Maintains...
Benzinga Newsdesk
Friday, February 16, 2024
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Cracking The Code: Understanding Analyst Reviews For AtriCure
Benzinga Insights
Needham Maintains Buy on AtriCure, Raises Pri...
Benzinga Newsdesk
Thursday, February 15, 2024
Recap: AtriCure Q4 Earnings
Benzinga Insights
AtriCure Q4 2023 Adj EPS $(0.21) Beats $(0.23...
Benzinga Newsdesk
Earnings Scheduled For February 15, 2024
Benzinga Insights
Wednesday, February 14, 2024
AtriCure's Earnings: A Preview
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch